A Phase 1 Safety Study of Evexomostat (SDX-7320) in Patients with Late-Stage Cancer: An Antiangiogenic, Insulin-Sensitizing Drug Conjugate Targeting METAP2.
- DOI
- 10.1158/2767-9764.crc-24-0627
- Published
- 2025 Jun 1
- Container
- Cancer research communications
- Publisher
- Not recorded
- Open access
- yes
Credibility signals
limited evidence Score 45/100 under policy 1.0.0. This is a metadata assessment, not a judgment of the paper's conclusions.
Show all credibility signals
- cautionDOI registered: No matching Crossref record was present in this response.
- cautionDOI resolves: No matching Crossref record was present in this response.
- not scoredDirectory of Open Access Journals: No matching DOAJ record was present in this response. No allow-list match; this is not evidence of low credibility.
- not scoredMEDLINE indexed: Not checked or no result supplied; no credibility inference made.
- not scoredOpenAlex core source: Not checked or no result supplied; no credibility inference made.
- not scoredKnown publisher allow-list: Not checked or no result supplied; no credibility inference made.
- not scoredROR affiliation: Not checked or no result supplied; no credibility inference made.
- not scoredRetraction Watch retraction: No retraction notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete.
- not scoredRetraction Watch expression of concern: No expression of concern notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete.
- not scoredRetraction Watch correction: No correction notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete.
- not scoredRetraction Watch reinstatement: No reinstatement notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete.
- supportingOpen access status: Normalized open-access status: open.
- not scoredPublication license: Not checked or no result supplied; no credibility inference made.
- not scoredPublication version: A publication version was supplied but is not scored.
- cautionMetadata completeness: 5 of 6 scored descriptive metadata groups are present; missing fields increase uncertainty.
Cite this work
BibTeX
@article{allodium:10.1158/2767-9764.crc-24-0627,
title = {A Phase 1 Safety Study of Evexomostat (SDX-7320) in Patients with Late-Stage Cancer: An Antiangiogenic, Insulin-Sensitizing Drug Conjugate Targeting METAP2.},
author = {Mita MM and Mita AC and Carver BJ and Shanahan JM and Mayes BA and Dufour PJ and Browning D and Anderson-Villaluz A and Petersen JS and Turnquist DJ and Cornelius P},
year = {2025},
journal = {Cancer research communications},
doi = {10.1158/2767-9764.crc-24-0627},
url = {https://doi.org/10.1158/2767-9764.crc-24-0627}
}RIS
TY - JOUR TI - A Phase 1 Safety Study of Evexomostat (SDX-7320) in Patients with Late-Stage Cancer: An Antiangiogenic, Insulin-Sensitizing Drug Conjugate Targeting METAP2. AU - Mita MM AU - Mita AC AU - Carver BJ AU - Shanahan JM AU - Mayes BA AU - Dufour PJ AU - Browning D AU - Anderson-Villaluz A AU - Petersen JS AU - Turnquist DJ AU - Cornelius P PY - 2025 JO - Cancer research communications DO - 10.1158/2767-9764.crc-24-0627 UR - https://doi.org/10.1158/2767-9764.crc-24-0627 ER -
APA
MM, M., AC, M., BJ, C., JM, S., BA, M., PJ, D., D, B., A, A., JS, P., DJ, T., & P, C. (2025). A Phase 1 Safety Study of Evexomostat (SDX-7320) in Patients with Late-Stage Cancer: An Antiangiogenic, Insulin-Sensitizing Drug Conjugate Targeting METAP2.. Cancer research communications. https://doi.org/10.1158/2767-9764.crc-24-0627
Source records
- pubmed · retrieved 2026-09-27T11:59:58.493Z
- europe-pmc · retrieved 2026-09-27T11:59:58.509Z